[1] Wu Y X, Sun X N, Zhang B Y et al. Marriage of radiotracers and total-body PET/CT rapid imaging system: current status and clinical advances[J]. American Journal of Nuclear Medicine and Molecular Imaging, 13, 195-207(2023).

[2] Sneddon D, Cornelissen B. Emerging chelators for nuclear imaging[J]. Current Opinion in Chemical Biology, 63, 152-162(2021).

[3] Kostelnik T I, Orvig C. Radioactive main group and rare earth metals for imaging and therapy[J]. Chemical Reviews, 119, 902-956(2019).

[4] Zhang S Q, Wang X K, Gao X et al. Radiopharmaceuticals and their applications in medicine[J]. Signal Transduction and Targeted Therapy, 10, 1(2025).

[5] Bodei L, Herrmann K, Schöder H et al. Radiotheranostics in oncology: current challenges and emerging opportunities[J]. Nature Reviews Clinical Oncology, 19, 534-550(2022).

[6] Bolcaen J, Kleynhans J, Nair S et al. A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma[J]. Theranostics, 11, 7911-7947(2021).

[7] Bormans G, Cleeren F. Radiopharmaceuticals for cancer imaging and therapy[J]. Pharmaceutics, 15, 2262(2023).

[8] Price E W, Orvig C. Matching chelators to radiometals for radiopharmaceuticals[J]. Chemical Society Reviews, 43, 260-290(2014).

[9] Sgouros G, Bodei L, McDevitt M R et al. Radiopharmaceutical therapy in cancer: clinical advances and challenges[J]. Nature Reviews Drug Discovery, 19, 589-608(2020).

[10] Hatcher-Lamarre J L, Sanders V A, Rahman M et al. Alpha emitting nuclides for targeted therapy[J]. Nuclear Medicine and Biology, 92, 228-240(2021).

[11] Haberkorn U, Giesel F, Morgenstern A et al. The future of radioligand therapy: α, β, or both[J]. Journal of Nuclear Medicine, 58, 1017-1018(2017).

[12] Boros E, Packard A B. Radioactive transition metals for imaging and therapy[J]. Chemical Reviews, 119, 870-901(2019).

[13] SHI Guang, CHENG Liang, WANG Kezheng. Research progress on synthesis methods of commonly used 11C labeled positron emitting radiopharmaceuticals[J]. Industrial Microbiology, 53, 40-44(2023).

[14] HUANG Xiaoyan, GAO Fei, ZHANG Yunhan et al. Research progress on Al18F labeled biomolecules[J]. Labeling Immunoassay and Clinical, 31, 1344-1351(2024).

[15] GONG Ming, SUN Dequn. Research advances of direct incorporation of fluorine- containing groups and 18F-labeling methods[J]. Organic Chemistry, 36, 1715-1740(2016).

[16] Morfin J F, Tóth É. Kinetics of Ga(NOTA) formation from weak Ga-citrate complexes[J]. Inorganic Chemistry, 50, 1-10378(2011).

[17] Smith R M, Martell A E[M]. Critical stability constants(1976).

[18] Pruszyński M, Majkowska-Pilip A, Loktionova N S et al. Radiolabeling of DOTATOC with the long-lived positron emitter 44Sc[J]. Applied Radiation and Isotopes, 70, 974-979(2012).

[19] Tsionou M I, Knapp C E, Foley C A et al. Comparison of macrocyclic and acyclic chelators for gallium-68 radiolabelling[J]. RSC Advances, 7, 4-49599(2017).

[20] Lattuada L, Barge A, Cravotto G et al. The synthesis and application of polyamino polycarboxylic bifunctional chelating agents[J]. Chemical Society Reviews, 40, 3019-3049(2011).

[21] Velikyan I, Maecke H, Langstrom B. Convenient preparation of 68Ga-based PET-radiopharmaceuticals at room temperature[J]. Bioconjugate Chemistry, 19, 569-573(2008).

[22] Carlucci G, Ippisch R, Slavik R et al. 68Ga-PSMA-11 NDA approval: a novel and successful academic partnership[J]. Journal of Nuclear Medicine, 62, 149-155(2021).

[23] Makarem A, Klika K D, Litau G et al. HBED-NN: a bifunctional chelator for constructing radiopharmaceuticals[J]. Journal of Organic Chemistry, 84, 7501-7508(2019).

[24] Boros E, Ferreira C L, Cawthray J F et al. Acyclic chelate with ideal properties for 68Ga PET imaging agent elaboration[J]. Journal of the American Chemical Society, 132, 1-15733(2010).

[25] Boros E, Ferreira C L, Yapp D T T et al. RGD conjugates of the H2dedpa scaffold: synthesis, labeling and imaging with 68Ga[J]. Nuclear Medicine and Biology, 39, 785-794(2012).

[26] Eplattenier F L, Murase I, Martell A E. New multidentate ligands. VI. chelating tendencies of N,N'-di(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid[J]. Journal of the American Chemical Society, 89, 837-843(1967).

[27] Boros E, Cawthray J F, Ferreira C L et al. Evaluation of the H2dedpa scaffold and its cRGDyK conjugates for labeling with 64Cu[J]. Inorganic Chemistry, 51, 6279-6284(2012).

[28] Breeman W A, de Jong M, Kwekkeboom D J et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives[J]. European Journal of Nuclear Medicine, 28, 1421-1429(2001).

[29] Milenic D E, Garmestani K, Chappell L L et al. In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications[J]. Nuclear Medicine and Biology, 29, 431-442(2002).

[31] Rahbar K, Ahmadzadehfar H, Kratochwil C et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients[J]. Journal of Nuclear Medicine, 58, 85-90(2017).

[32] Kam B L R, Teunissen J J M, Krenning E P et al. Lutetium-labelled peptides for therapy of neuroendocrine tumours[J]. European Journal of Nuclear Medicine and Molecular Imaging, 39, 103-112(2012).

[33] Banerjee S, Pillai M A, Russ Knapp F F. Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications[J]. Chemical Reviews, 115, 2934-2974(2015).

[34] Price E W, Cawthray J F, Bailey G A et al. H4octapa: an acyclic chelator for 111In radiopharmaceuticals[J]. Journal of the American Chemical Society, 134, 8670-8683(2012).

[35] Platas-Iglesias C, Mato-Iglesias M, Djanashvili K et al. Lanthanide chelates containing pyridine units with potential application as contrast agents in magnetic resonance imaging[J]. Chemistry, 10, 3579-3590(2004).

[36] Price E W, Zeglis B M, Cawthray J F et al. H4octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy[J]. Journal of the American Chemical Society, 135, 1-12721(2013).

[37] Li L, Kuo H T, Wang X Z et al. tBu4octapa-alkyl-NHS for metalloradiopeptide preparation[J]. Dalton Transactions, 49, 7605-7619(2020).

[38] Li L, de Guadalupe Jaraquemada-Peláez M, Kuo H T et al. Functionally versatile and highly stable chelator for 111In and 177Lu: proof-of-principle prostate-specific membrane antigen targeting[J]. Bioconjugate Chemistry, 30, 1539-1553(2019).

[39] Cieslik P, Kubeil M, Zarschler K et al. Toward personalized medicine: one chelator for imaging and therapy with lutetium-177 and actinium-225[J]. Journal of the American Chemical Society, 144, 2-21567(2022).

[40] Geenen L, Nonnekens J, Konijnenberg M et al. Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours[J]. Nuclear Medicine and Biology, 102–103, 1-11(2021).

[41] Kong G, Callahan J, Hofman M S et al. High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours[J]. European Journal of Nuclear Medicine and Molecular Imaging, 44, 476-489(2017).

[42] Chakravarty R, Chakraborty S, Dash A. A systematic comparative evaluation of 90Y-labeled bifunctional chelators for their use in targeted therapy[J]. Journal of Labelled Compounds & Radiopharmaceuticals, 57, 65-74(2014).

[43] Breeman W A P, de Jong M, Visser T J et al. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities[J]. European Journal of Nuclear Medicine and Molecular Imaging, 30, 917-920(2003).

[44] Bokhari T H, Butt M B, Hina S et al. A review on 90Y-labeled compounds and biomolecules[J]. Journal of Radioanalytical and Nuclear Chemistry, 314, 1487-1496(2017).

[45] Price E W, Edwards K J, Carnazza K E et al. A comparative evaluation of the chelators H4octapa and CHX-A″-DTPA with the therapeutic radiometal 90Y[J]. Nuclear Medicine and Biology, 43, 566-576(2016).

[46] Hoffman T J, Gali H, Smith C J et al. Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells[J]. Journal of Nuclear Medicine, 44, 823-831(2003).

[47] Breeman W A, Jong M D, Bernard B F et al. Pre-clinical evaluation of [111In-DTPA-Pro(1), Tyr(4)] bombesin, a new radioligand for bombesin-receptor scintigraphy[J]. International Journal of Cancer, 83, 657-663(1999).

[48] Garrison J C, Rold T L, Sieckman G L et al. Evaluation of the pharmacokinetic effects of various linking group using the 111In-DOTA-X-BBN(7-14)NH2 structural paradigm in a prostate cancer model[J]. Bioconjugate Chemistry, 19, 1803-1812(2008).

[49] Opacic T, Paefgen V, Lammers T et al. Status and trends in the development of clinical diagnostic agents[J]. WIREs Nanomedicine and Nanobiotechnology, 9, e1441(2017).

[50] Marcu L, Bezak E, Allen B J. Global comparison of targeted alpha vs. targeted beta therapy for cancer: in vitro, in vivo and clinical trials[J]. Critical Reviews in Oncology/Hematology, 123, 7-20(2018).

[51] Price E W, Zeglis B M, Lewis J S et al. H6phospa-trastuzumab: bifunctional methylenephosphonate-based chelator with 89Zr, 111In and 177Lu[J]. Dalton Transactions, 43, 119-131(2014).

[52] Umbricht C A, Benešová M, Schibli R et al. Preclinical development of novel PSMA-targeting radioligands: modulation of albumin-binding properties to improve prostate cancer therapy[J]. Molecular Pharmaceutics, 15, 2297-2306(2018).

[53] Nayak T K, Garmestani K, Milenic D E et al. PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab[J]. Journal of Nuclear Medicine, 53, 113-120(2012).

[54] Wharton L, Jaraquemada-Peláez M G, Zhang C C et al. H4picoopa─Robust chelate for 225Ac/111In theranostics[J]. Bioconjugate Chemistry, 33, 1900-1921(2022).

[55] Kręcisz P, Stefańska K, Studziński J et al. Radiocopper in radiopharmacy and medical use: current status and perspective[J]. Journal of Medicinal Chemistry, 68, 2356-2376(2025).

[56] Yang H, Gao F, McNeil B et al. Synthesis of DOTA-pyridine chelates for 64Cu coordination and radiolabeling of αMSH peptide[J]. EJNMMI Radiopharmacy and Chemistry, 6, 3(2021).

[57] Lee I, Kim M H, Lee K et al. Comparison of the effects of DOTA and NOTA chelators on 64Cu-cudotadipep and 64Cu-cunotadipep for prostate cancer[J]. Diagnostics, 13, 2649(2023).

[58] Malmberg J, Perols A, Varasteh Z et al. Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts[J]. European Journal of Nuclear Medicine and Molecular Imaging, 39, 481-492(2012).

[59] Liu H H, Zhang X J, Zhang J F et al. Comparison of 64Cu-DOTA-PSMA-3Q and 64Cu-NOTA-PSMA-3Q utilizing NOTA and DOTA as bifunctional chelators in prostate cancer: preclinical assessment and preliminary clinical PET/CT imaging[J]. European Journal of Nuclear Medicine and Molecular Imaging, 52, 2792-2803(2025).

[60] Hao G Y, Mastren T, Silvers W et al. Copper-67 radioimmunotheranostics for simultaneous immunotherapy and immuno-SPECT[J]. Scientific Reports, 11, 3622(2021).

[61] De Silva R A, Jain S, Lears K A et al. Copper-64 radiolabeling and biological evaluation of bifunctional chelators for radiopharmaceutical development[J]. Nuclear Medicine and Biology, 39, 1099-1104(2012).

[62] Pandya D N, Bhatt N, Dale A V et al. New bifunctional chelator for 64Cu-immuno-positron emission tomography[J]. Bioconjugate Chemistry, 24, 1356-1366(2013).

[63] García-Toraño E, Peyrés V, Roteta M et al. Standardisation and precise determination of the half-life of 44Sc[J]. Applied Radiation and Isotopes, 109, 314-318(2016).

[64] Vaughn B A, Ahn S H, Aluicio-Sarduy E et al. Chelation with a twist: a bifunctional chelator to enable room temperature radiolabeling and targeted PET imaging with scandium-44[J]. Chemical Science, 11, 333-342(2019).

[65] Pniok M, Kubíček V, Havlíčková J et al. Thermodynamic and kinetic study of scandium(III) complexes of DTPA and DOTA: a step toward scandium radiopharmaceuticals[J]. Chemistry, 20, 7944-7955(2014).

[66] Nagy G, Szikra D, Trencsényi G et al. AAZTA: an ideal chelating agent for the development of 44Sc PET imaging agents[J]. Angewandte Chemie (International Ed.), 56, 2118-2122(2017).

[67] McDevitt M R, Ma D S, Simon J et al. Design and synthesis of 225Ac radioimmunopharmaceuticals[J]. Applied Radiation and Isotopes, 57, 841-847(2002).

[68] Jurcic J G, Rosenblat T L. Targeted alpha-particle immunotherapy for acute myeloid leukemia[M]. American Society of Clinical Oncology Educational Book, e126-e131(2014).

[69] Maguire W F, McDevitt M R, Smith-Jones P M et al. Efficient 1-step radiolabeling of monoclonal antibodies to high specific activity with 225Ac for α-particle radioimmunotherapy of cancer[J]. Journal of Nuclear Medicine, 55, 1492-1498(2014).

[70] Thiele N A, Brown V, Kelly J M et al. An eighteen-membered macrocyclic ligand for actinium-225 targeted alpha therapy[J]. Angewandte Chemie International Edition, 56, 1-14717(2017).

[71] Li L, Rousseau J, Jaraquemada-Peláez M G et al. 225Ac-H4py4pa for targeted alpha therapy[J]. Bioconjugate Chemistry, 32, 1348-1363(2021).

[72] Meijs W E, Herscheid J D, Haisma H J et al. Evaluation of desferal as a bifunctional chelating agent for labeling antibodies with Zr-89[J]. International Journal of Radiation Applications and Instrumentation Part A, Applied Radiation and Isotopes, 43, 1443-1447(1992).

[73] Deri M A, Ponnala S, Zeglis B M et al. Alternative chelator for 89Zr radiopharmaceuticals: radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO)[J]. Journal of Medicinal Chemistry, 57, 4849-4860(2014).

[74] Patra M, Bauman A, Mari C et al. An octadentate bifunctional chelating agent for the development of stable zirconium-89 based molecular imaging probes[J]. Chemical Communications, 50, 1-11525(2014).

[75] Vugts D J, Klaver C, Sewing C et al. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET[J]. European Journal of Nuclear Medicine and Molecular Imaging, 44, 286-295(2017).

[76] Raavé R, Sandker G, Adumeau P et al. Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for 89Zr-immunoPET[J]. European Journal of Nuclear Medicine and Molecular Imaging, 46, 1966-1977(2019).

[77] Gorden A E V, Xu J D, Raymond K N et al. Rational design of sequestering agents for plutonium and other actinides[J]. Chemical Reviews, 103, 4207-4282(2003).

[78] Sturzbecher-Hoehne M, Choi T A, Abergel R J. Hydroxypyridinonate complex stability of group (IV) metals and tetravalent f-block elements: the key to the next generation of chelating agents for radiopharmaceuticals[J]. Inorganic Chemistry, 54, 3462-3468(2015).

[79] Petrik M, Haas H, Schrettl M et al. In vitro and in vivo evaluation of selected 68Ga-siderophores for infection imaging[J]. Nuclear Medicine and Biology, 39, 361-369(2012).

[80] Pandya D N, Bhatt N, Yuan H et al. Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development[J]. Chemical Science, 8, 2309-2314(2017).

[81] Deri M A, Zeglis B M, Francesconi L C et al. PET imaging with 89Zr: from radiochemistry to the clinic[J]. Nuclear Medicine and Biology, 40, 3-14(2013).

[82] Imura R, Jang J, Ozeki A N et al. Click chemistry enables [89Zr] Zr-DOTA radioimmunoconjugation for theranostic 89Zr-immunoPET[J]. Bioconjugate Chemistry, 35, 1744-1754(2024).

[83] Li M S, Sagastume E A, Lee D et al. 203/212Pb theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer[J]. Current Medicinal Chemistry, 27, 7003-7031(2020).

[84] Chappell L L, Dadachova E, Milenic D E et al. Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb[J]. Nuclear Medicine and Biology, 27, 93-100(2000).

[85] Milenic D E, Garmestani K, Brady E D et al. α-particle radioimmunotherapy of disseminated peritoneal disease using a 212Pb-labeled radioimmunoconjugate targeting HER2[J]. Cancer Biotherapy and Radiopharmaceuticals, 20, 557-568(2005).

[86] Banerjee S R, Minn I, Kumar V et al. Preclinical evaluation of 203/212Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer[J]. Journal of Nuclear Medicine, 61, 80-88(2020).

[87] Lee D, Li M S, Liu D J et al. Structural modifications toward improved lead-203/lead-212 peptide-based image-guided alpha-particle radiopharmaceutical therapies for neuroendocrine tumors[J]. European Journal of Nuclear Medicine and Molecular Imaging, 51, 1147-1162(2024).